{"id":69241,"date":"2020-07-13T16:00:56","date_gmt":"2020-07-13T10:30:56","guid":{"rendered":"http:\/\/localhost\/one\/?p=69241"},"modified":"2025-06-30T14:56:23","modified_gmt":"2025-06-30T09:26:23","slug":"compulsory-license-remdesivir-patent-news-epo-covid19","status":"publish","type":"post","link":"https:\/\/www.bananaip.com\/intellepedia\/compulsory-license-remdesivir-patent-news-epo-covid19\/","title":{"rendered":"CPI(M) asks Government to issue compulsory license for Remdesivir, EPO creates search strategies to help fight against COVID-19 and more patent news"},"content":{"rendered":"<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\">In this week\u2019s Patent News \u2013 CPI(M) asks Government to issue compulsory license for manufacturing generic versions of drug \u2013 Remdesivir; EPO creates search strategies to aid scientists distinguish documents relevant to fight the COVID-19 pandemic; EUIPO and EPO to jointly host online conference on Additive Manufacturing<\/span><\/p>\n<h2 style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif; color: #ff6600;\"><strong>INDIA PATENT NEWS UPDATE<\/strong><\/span><\/h2>\n<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\"><strong>CPI(M) asks Government to issue compulsory license for manufacturing generic versions of drug &#8211; Remdesivir<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\">The Communist Party of India (Marxist) has reportedly requested the Central Government to issue a compulsory license to manufactures for the production of generic versions of drug \u2013 Remdesivir. Remdesivir, originally an anti-viral, is now being used to treat some symptoms of a COVID patient. The CPI(M) has asked the Government to invoke Section 92 of the Patents Act, 1970 to \u201cbreak the patent monopoly of Gilead Sciences.\u201d Gilead Sciences previously signed non-exclusive voluntary licensing agreements with generic pharmaceutical manufacturers in India, Egypt and Pakistan. As per this agreement, five pharmaceutical companies in India have the exclusive right to manufacture and sell the drug in 127 different countries. CPI(M) has said \u201cUnder Clause 92 of India\u2019s Patents Act, India has the right to issue a compulsory license to manufacture the drug. Under Clause 92A of the Patents Act, compulsory license can even be issued for export to countries that may require the drug and not have the capability to manufacture it.\u201d<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\">You make click <strong><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/www.gilead.com\/purpose\/advancing-global-health\/covid-19\/voluntary-licensing-agreements-for-remdesivir\" target=\"_blank\" rel=\"noopener\">here<\/a><\/span><\/strong> to access the official press release by Gilead Sciences on Voluntary Licensing Agreements for Remdesivir.<\/span><\/p>\n<h2 style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif; color: #ff6600;\"><strong>INTERNATIONAL PATENT NEWS UPDATE<\/strong><\/span><\/h2>\n<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\"><strong>EPO creates search strategies to aid scientists distinguish documents relevant to fight the COVID-19 pandemic<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\">As per the latest notification by the European Patent Office (EPO), Patent Examiners and Patent Analysts of the EPO have created search strategies or search statements for scientists to help them identify relevant documents in all technical fields related to combating COVID-19. According to the EPO, the search strategies are suited to be implemented on Espacenet, EPO\u2019s online patent search interface.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\">The search strategies have been placed under four main headings, namely \u2013<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li><span style=\"font-family: 'book antiqua', palatino, serif;\">Vaccines<\/span><\/li>\n<li><span style=\"font-family: 'book antiqua', palatino, serif;\">Overview of candidate therapies for COVID-19<\/span><\/li>\n<li><span style=\"font-family: 'book antiqua', palatino, serif;\">Candidate antiviral and symptomatic therapeutics<\/span><\/li>\n<li><span style=\"font-family: 'book antiqua', palatino, serif;\">Nucleic acids and antibodies to fight coronavirus<\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\">You may click <strong><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/www.epo.org\/news-events\/in-focus\/fighting-coronavirus.html\" target=\"_blank\" rel=\"noopener\">here<\/a><\/span><\/strong> for more information.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\"><strong>EUIPO and EPO to jointly host online conference on Additive Manufacturing<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\">The European Union Intellectual Property Office (EUIPO) and the European Patent Office (EPO) will be hosting an online conference on Additive Manufacturing, most commonly referred to as 3D Printing. The four-day digital conference will be held between the 13<sup>th<\/sup> and 16<sup>th<\/sup> of July 2020. While recognizing the opportunities presented by 3D Printing, the EPO aims to understand the challenges posed by the technology with reference to Intellectual Property as 3D printing is likely to have an impact on, patents, designs and copyrights. As per the notification, the conference will create a platform for experts, policy makers, inventors, attorneys and entrepreneurs to share their standpoints. The conference is likely to be beneficial to SMEs, Researchers and IP professionals. Interested persons may click <strong><span style=\"color: #0000ff;\">here<\/span><\/strong> to Register for the event and <strong><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/www.epo.org\/news-events\/in-focus\/fighting-coronavirus\/innovation.html\" target=\"_blank\" rel=\"noopener\">here<\/a> <\/span><\/strong>for more information.<\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\"><strong><em>Authored and compiled by Vibha Amarnath<\/em><\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"text-decoration: underline;\"><span style=\"color: #ff6600;\"><strong><span style=\"font-family: 'book antiqua', palatino, serif;\"><em>About BIP\u2019s Patent Attorneys<\/em><\/span><\/strong><\/span><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\"><em>The patent news bulletin is brought to you by the patent division of BananaIP Counsels, a top patent and IP firm in India. Led by Senior Partners, Somashekar Ramakrishna, Nitin Nair and Vinita Radhakrishnan, BIP\u2019s Patent Attorneys are among the leading patent practitioners in the country. They work with clients such as Mahindra and Mahindra, Samsung, HCL, Eureka Forbes, to name a few. The patent attorneys at BIP have strong technical and legal expertise in areas such as IT\/Software, Artificial Intelligence (AI), Machine Learning, Data Analytics, Electronics and Telecommunication, Mechanical, Automotive, Green Energy, Traditional Medicine and Bio\/Pharma domains. The firm is a first choice for clients looking for support in patent filing, prosecution, management and strategy in India, and across the world.<\/em><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\"><em>This weekly patent news bulletin is a part of their pro bono work, and is aimed at spreading patent awareness. You are free to share the news with appropriate attribution and backlink to the source.<\/em><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\"><em>If you have any questions, or need any clarifications, please feel free to write to<strong><span style=\"color: #0000ff;\">\u00a0<\/span><\/strong><\/em><strong><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"mailto:contact@bananaip.com\">contact@bananaip.com<\/a><\/span><\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span style=\"font-family: 'book antiqua', palatino, serif;\"><em>Disclaimer<\/em><em>: Kindly note that the news bulletin has been put together from different sources, primary and secondary, and BananaIP\u2019s reporters may not have verified all the news published in the bulletin. You may write to<strong><span style=\"color: #0000ff;\">\u00a0<\/span><\/strong><strong><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"mailto:contact@bananaip.com\">contact@bananaip.com<\/a><\/span><\/strong> for corrections and take down.<\/em><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The CPI(M) has urged the Indian government to issue a compulsory license for Remdesivir to facilitate generic manufacturing. Additionally, the EPO has developed new patent search strategies for COVID-19, and an upcoming EUIPO-EPO conference will address intellectual property issues in additive manufacturing.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"iawp_total_views":0,"footnotes":""},"categories":[6,14],"tags":[11051,11050,1073,4355,906,163,5,4174],"class_list":["post-69241","post","type-post","status-publish","format-standard","hentry","category-intellectual-property","category-patents","tag-3d-printing","tag-additive-manufacturing","tag-compulsory-license","tag-covid-19-patents","tag-epo","tag-indian-patent-law","tag-intellectual-property","tag-remdesivir"],"_links":{"self":[{"href":"https:\/\/www.bananaip.com\/intellepedia\/wp-json\/wp\/v2\/posts\/69241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bananaip.com\/intellepedia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bananaip.com\/intellepedia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bananaip.com\/intellepedia\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bananaip.com\/intellepedia\/wp-json\/wp\/v2\/comments?post=69241"}],"version-history":[{"count":2,"href":"https:\/\/www.bananaip.com\/intellepedia\/wp-json\/wp\/v2\/posts\/69241\/revisions"}],"predecessor-version":[{"id":141116,"href":"https:\/\/www.bananaip.com\/intellepedia\/wp-json\/wp\/v2\/posts\/69241\/revisions\/141116"}],"wp:attachment":[{"href":"https:\/\/www.bananaip.com\/intellepedia\/wp-json\/wp\/v2\/media?parent=69241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bananaip.com\/intellepedia\/wp-json\/wp\/v2\/categories?post=69241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bananaip.com\/intellepedia\/wp-json\/wp\/v2\/tags?post=69241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}